Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. Results from Marea's Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile.
'We are excited to have our MAR001 Phase 2a clinical results and preclinical data recognized within the broader scientific community through these publications in The Lancet and eBioMedicine,' said Ethan Weiss, M.D., chief scientific officer of Marea. 'These findings validate ANGPTL4 inhibition and the ability of MAR001 to safely and effectively reduce remnant cholesterol and triglycerides, which align with genetic findings and support further development in addressing atherosclerotic cardiovascular disease risk. We look forward to initiating a Phase 2b trial of MAR001 in the second quarter of 2025.'
About Remnant Cholesterol
Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes, or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function.
About MAR001
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes.
MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol.
Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Women's symptoms 'overlooked' in menopausal stages
Women going through perimenopause are experiencing debilitating hot flushes and night sweats that are often untreated, as a study reveals the prevalence of symptoms during hormonal transitions. Perimenopause is a transitional period before menopause, where levels of oestrogen begin to decrease, bringing with it a range of symptoms. A first of its kind study of more than 5500 women by Monash University published in The Lancet Diabetes and Endocrinology examined the similarities and differences in symptoms across the stages of menopause. Almost 40 per cent of perimenopausal women in the study experienced debilitating vasomotor symptoms (VMS) such as hot flushes and night sweats. While it was already known that VMS symptoms were typical in menopause, the study showed a new onset was highly specific to perimenopause, senior author Susan Davis said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. Other symptoms such as poor memory and low mood were found at various stages, but vaginal dryness was the most distinctive symptom from pre-menopause to perimenopause, she said. "While other symptoms might emerge in the perimenopausal stage, they lack specificity to that stage as these other symptoms are also common in pre-menopausal women." A major finding in the study was that women with regular cycles but changed menstrual flow and VMS who are classified as pre-menopausal have a similar severity of symptoms as perimenopausal women. "This finding supports the likelihood of perimenopause commencing before menstrual cycles vary by at least a week, and that women whose periods have become much heavier or much lighter and who also have VMS should be considered as having entered their perimenopause," Professor Davis said. The research was expected to transform women's health treatment, particularly in menopause, which had been overlooked for too long, Monash Women's Health Alliance chair Jill Hennessy said. "Too many go untreated for debilitating symptoms like hot flushes and night sweats," she said. "By defining the symptoms that truly mark this transition, this study empowers women and clinicians alike with better knowledge and tools to improve women's health and wellbeing." The study authors hoped the findings would improve how medical professionals identified and managed transitions in menopause. Many women were overlooked in being classified within a menopausal stage if they had regular cycles or no longer menstruated due to a hysterectomy, first author Rakib Islam said. "Our findings support a more symptom-based approach, enabling earlier recognition of perimenopause and more timely care," he said.
Tom's Guide
2 days ago
- Tom's Guide
Fibermaxxing is trending right now — here's what to know before you try it
Protein has long been the poster nutrient of the fitness and health world, essential for building muscle, aiding recovery, and keeping you feeling full. But recently, fiber has started to share the spotlight. Rather than replacing protein, fiber is being recognized as an overlooked powerhouse with benefits for gut health, digestion, skin, metabolism and even heart health. This growing interest has sparked a trend called 'fibermaxxing,' where people are finding ways to add more fiber to their diets to improve digestion, clear up their skin and support metabolic health. But is this just a passing online fad, or is there real science behind it? While official guidelines suggest women aim for around 25 grams of fiber per day and men for about 31 grams, most Americans fall short. According to the American Journal of Lifestyle Medicine, just 5% of the U.S. population meets these recommendations. The original Nutribullet makes it easy to load up on fiber-rich fruits and veggies. With 600 watts of power and a no-fuss design, it turns whole foods into smooth, nutrient-packed drinks in seconds. Fibermaxxing aims to close that gap by encouraging people to add more fiber-rich foods like oats, lentils, berries, beans,and leafy greens to their daily meals. It can also involve sourcing little top-ups like adding chia seeds to recipes or swapping in high-fiber snacks and supplements. Multiple studies have shown that hitting your fiber goals isn't just good for digestion, it's linked to a lower risk of heart disease, diabetes, and other chronic health problems. According to one study, higher fiber consumption is linked to a significantly lower risk of cardiovascular disease, type 2 diabetes and colorectal cancer. According to a study published in The Lancet, higher fiber consumption is linked to a significantly lower risk of cardiovascular disease, type 2 diabetes and colorectal cancer. Fiber helps regulate blood sugar, promotes healthy gut bacteria, and reduces inflammation. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. However, experts caution that increasing fiber too quickly can lead to digestive discomfort, such as bloating or gas. The Mayo Clinic recommends gradually adding fiber to your diet while drinking plenty of water. This gives your digestive system time to adjust and helps you get the full benefits of fiber without the side effects. There's no denying a fiber-rich diet comes with plenty of benefits from keeping your digestion on track to supporting heart health and managing blood sugar. The key is to increase fiber gradually and focus on whole foods like beans, berries and greens. Don't forget to drink plenty of water to avoid any tummy troubles. Everyone's body reacts differently so if you're thinking about making big changes, it's a good idea to chat with a healthcare professional first. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Yahoo
2 days ago
- Yahoo
Revealed: The number of steps you need to improve your life expectancy
Walking 7,000 steps a day is the sweet spot for preventing many chronic diseases that can lead to an early death, a major study has shown. While the goal of 10,000 daily steps has become firmly established in the public consciousness, an international team of researchers found even a modest amount of walking brings major benefits. British scientists said it finally 'debunked the myth' of 10,000 steps and should encourage people to try and hit the lower target. The major review of 57 studies involving 160,000 adults, which was published in The Lancet, concluded that for most conditions health benefits tended to level off beyond 7,000 steps. Hitting 7,000 steps a day was found to reduce all-cause-mortality by 47 per cent, cardiovascular disease by 25 per cent, cancer by six per cent, diabetes by 14 per cent, dementia by 38 per cent and depression by 22 per cent. Health benefits were also apparent from 4,000 steps when compared to 'inactive' people who walked just 2,000, the study led by the University of Sydney found. Every extra 1,000 steps brought better outcomes, researchers found. Commenting on the study, Steven Harridge, professor of human and applied physiology at King's College London, said: 'Humans are designed to be physically active – our evolutionary heritage as hunter gatherers. 'There has been debate about the amount of activity an individual should be doing with 10,000 steps as a generalised target, not well evidenced. 'This paper shows that 7,000 steps is sufficient for reducing the risk for most diseases covered, and 10, 000 steps does not confer much additional benefit.' According to World Health Organisation data, insufficient physical activity is the fourth most frequent cause of death in the world, with 3.2 million deaths a year related to physical inactivity. Many health organisations recommend hitting 10,000 steps a day, although there is little evidence for the target, which is believed to have arisen from a Japanese marketing campaign in the 1960s. In the run-up to the 1964 Tokyo Olympics, the company Yamasa sought to capitalise on the sudden interest in fitness, so designed the world's first wearable step-counter. They called it the Manpo-kei, or '10,000-step meter'. The company appears to have chosen the figure at random, as a fun goal, but it has stuck ever since. The new paper found that for heart disease, walking more than 7,000 steps was beneficial, but for most conditions there was little gain from putting in more said it was still unclear why walking brings such striking benefits but said it is likely to increase cardiorespiratory fitness, which is known to be positively associated with better health and all-cause mortality outcomes. Commenting on the research, Dr Daniel Bailey, an expert in sedentary behaviour and health at Brunel University of London, said the 7,000 steps target was more achievable for many people than 10,000 steps. 'Just adding more steps from your starting point can have important benefits for health,' he said. 'This study adds to existing evidence by showing that the more steps people do, the less their risk of developing different health conditions. 'The finding that doing 5,000-7,000 steps per day is beneficial, is an important addition to the literature which helps to debunk the myth that 10,000 steps per day should be the target for optimal health.' The Alzheimer's Society also welcomed the study saying it demonstrated that inactivity is a major risk factor for dementia. Dr Richard Oakley, associate director of research and innovation at the charity said: 'It adds to the evidence that what's good for the heart is good for the head.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
